Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence
Both semaglutide GLP-1 and Zepbound are highly effective prescription medications approved for weight management, but individual results may vary
Wang, L., Xu, R., Kaelber, D
Measurable weight loss usually becomes apparent by weeks 3-4
71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons
GLP-1 Bridge is a workaround, since it operates outside the Part D benefit, runs on CMSs demonstration authority, and expires on December 31, 2027